Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Modern approaches to the treatment of fibromyalgia

https://doi.org/10.14412/2074-2711-2021-5-83-89

Full Text:

Abstract

Fibromyalgia (FM) occurs in 5–12% of patients but is relatively rarely diagnosed, so most patients do not receive adequate treatment. The review analyses pharmacological and non-pharmacological methods of FM treatment. Data suggests that antidepressants (duloxetine, milnacipran, amitriptyline) and antiepileptics (pregabalin, gabapentin) are most effective. Among non-pharmacological methods, the effectiveness of cognitive-behavioral and mindfulness therapy, kinesiotherapy, and biofeedback has been shown. In the management of patients with FM, a combination of non-pharmacological methods and medications can reduce pain and improve the quality of life.

About the Authors

T. I. Nasonova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Tatiana Igorevna Nasonova

Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine

1, Rossolimo St., Build. 1, Moscow 119021



A. Kh. Mukhametzyanova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine

1, Rossolimo St., Build. 1, Moscow 119021



G. R. Tabeyeva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine

1, Rossolimo St., Build. 1, Moscow 119021



P. A. Chernousov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine

1, Rossolimo St., Build. 1, Moscow 119021



References

1. Arnold LM, Bennett RM, Crofford LJ, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611-28. doi: 10.1016/j.jpain.2018.10.008

2. Häuser W, Kosseva M, Üceyler N, et al. Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with meta-analysis. Arthritis Care Res. 2011;63(6):808-20. doi: 10.1002/acr.20328

3. Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: Sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22(1):151-6. doi: 10.1002/art.1780380104

4. Storozhenko ON. Rasprostranennost' i faktory riska sindromov fibromialgii i khronicheskoy generalizovannoy boli v populyatsii g. Yekaterinburga: Diss. … kand. med. nauk [Prevalence and risk factors for fibromyalgia syndromes and chronic generalized pain in the population of Yekaterinburg: Diss. ... cand. med. sci.]. Moscow; 2004. 171 p. Available from: https://rusneb.ru/catalog/000199_000009_004060836 (In Russ.).

5. Jones GT, Atzeni F, Beasley M, et al. The prevalence of fibromyalgia in the general population: A comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheum. 2015;67(2):568-75. doi: 10.1002/art.38905

6. Sawaddiruk P, Paiboonworachat S, Chattipakorn N, et al. Alterations of brain activity in fibromyalgia patients. J Clin Neurosci. 2017 Apr;38:13-22. doi: 10.1016/j.jocn.2016.12.014. Epub 2017 Jan 10.

7. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2016;76(2):318-28. doi: 10.1136/annrheumdis-2016-209724

8. Clauw DJ. Fibromyalgia: A clinical review. JAMA. 2014 Apr 16;311(15):1547-55. doi: 10.1001/jama.2014.3266

9. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29(11):1371-7. doi: 10.1002/art.1780291110

10. Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum. 1986;29(5):655-9. doi: 10.1002/art.1780290510

11. Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988;31(12):1535-42. doi: 10.1002/art.1780311210

12. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51(1):9-13. doi: 10.1002/art.20076

13. Arnold LM, Keck PE, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000;41(2):104-13. doi: 10.1176/appi.psy.41.2.104

14. O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15(9):659-66. doi: 10.1046/j.15251497.2000.06279.x

15. Üceyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008 Sep 15;59(9):1279-98. doi: 10.1002/art.24000

16. Häuser W, Petzke F, Üceyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2011 Mar;50(3):532-43. doi: 10.1093/rheumatology/keq354. Epub 2010 Nov 14.

17. Rico-Villademoros F, Slim M, Calandre EP. Amitriptyline for the treatment of fibromyalgia: a comprehensive review. Exp Rev Neurother. 2015;15(10):1123-50. doi: 10.1586/14737175.2015.1091726. Epub 2015 Sep 22.

18. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505-21. doi: 10.1016/j.jpain.2010.01.002. Epub 2010 Apr 24.

19. Häuser W, Urrutia G, Tort S, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD010292. doi: 10.1002/14651858.cd010292

20. Welsch P, Üceyler N, Klose P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018 Feb 28;2(2):CD010292. doi: 10.1002/14651858.cd010292.pub2

21. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment o f fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974-84. doi: 10.1002/art.20485

22. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15. doi: 10.1016/j.pain.2005.06.031

23. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432-44. doi: 10.1016/j.pain.2008.02.024

24. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(S1):S27-S35. doi: 10.1002/hup.622

25. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32(10):1975-85.

26. Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol. 2010 Apr;37(4):851-9. doi: 10.3899/jrheum.090884. Epub 2010 Feb 15.

27. Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2010;62(9):2745-56. doi: 10.1002/art.27559

28. Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clin J Pain. Nov-Dec 2012;28(9):775-81. doi: 10.1097/ajp.0b013e3182510295

29. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014 Jan 3;(1):CD007115. doi: 10.1002/14651858.cd007115.pub3

30. Murakami M, Osada K, Ichibayashi H, et al. An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia. Mod Rheumatol. 2017;27(4):688-95. doi: 10.1080/14397595.2016.1245237. Epub 2016 Oct 31..

31. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988-2004. doi: 10.1016/j.clinthera.2008.11.009

32. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009 Feb;36(2):398-409. doi: 10.3899/jrheum.080734

33. Sayar K, Aksu G, Ak I, et al. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;37(11):1561-5. doi: 10.1345/aph.1d112

34. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013 Nov 11;2013(11):CD010567. doi: 10.1002/14651858.cd010567

35. Moore A, Wiffen P, Kalso E. Antiepileptic drugs for neuropathic pain and fibromyalgia. JAMA. 2014;312(2):182. doi: 10.1001/jama.2014.6336

36. Puiu T, Kairys AE, Pauer L, et al. Association of Alterations in Gray Matter Volume With Reduced Evoked-Pain Connectivity Following Short-Term Administration of Pregabalin in Patients With Fibromyalgia. Arthritis Rheum. 2016;68(6):1511-21. doi: 10.1002/art.39600

37. Häuser W, Bernardy K, Üceyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin – a meta-analysis of randomized controlled trials. Pain. 2009;145(1):69-81. doi: 10.1016/j.pain.2009.05.014. Epub 2009 Jun 17.

38. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336-44. doi: 10.1002/art.22457

39. Cooper TE, Derry S, Wiffen PJ, et al. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017 Jan 3;1(1):CD012188. doi: 10.1002/14651858.cd012188.pub2

40. Moore RA, Wiffen PJ, Derry S, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014 Apr 27;2014(4):CD007938. doi: 10.1002/14651858.CD007938.pub3

41. Andrew R, Derry S, Taylor RS, et al. The Costs and Consequences of Adequately Managed Chronic Non-Cancer Pain and Chronic Neuropathic Pain. Pain Pract. 2014 Jan;14(1):79-94. doi: 10.1111/papr.12050. Epub 2013 Mar 6.

42. Üceyler N, Sommer C, Walitt B, et al. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013 Oct 16;(10):CD010782. doi: 10.1002/14651858.cd010782

43. Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016 Sep 29;9(9):CD011790. doi: 10.1002/14651858.cd011790.pub2

44. Derry S, Wiffen PJ, Häuser W, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017 Mar 27;3(3):CD012332. doi: 10.1002/14651858.cd012332.pub2

45. Goldenberg DL, Clauw DJ, Palmer RE, et al. Opioid Use in Fibromyalgia: A Cautionary Tale. Mayo Clinic Proc. 2016;91(5):640-8. doi: 10.1016/j.mayocp.2016.02.002. Epub 2016 Mar 11.

46. Häuser W, Jones G. Psychological therapies for chronic widespread pain and fibromyalgia syndrome. Best Pract Res Clin Rheumatol. 2019;33(3):101416. doi: 10.1016/j.berh.2019.05.001

47. Köllner V, Bernardy K, Greiner W, et al. Psychotherapy and psychological procedures: updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):266-73. doi: 10.1007/s00482-017-0204-3

48. Beck JS. Cognitive behavior therapy: basics and beyond. 2 nd ed. New York: The Guilford Press; 2011.

49. Bernardy K, Klose P, Welsch P, et al. Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome – A systematic review and meta-analysis of randomized controlled trials. Eur J Pain. 2018;22(2):242-60. doi: 10.1002/ejp.1121

50. Haugmark T, Hagen KB, Smedslund G, Zangi HA. Mindfulness- and acceptance-based interventions for patients with fibromyalgia A systematic review and meta-analyses. PLoS One. 2019 Sep 3;14(9):e0221897. doi: 10.1371/journal.pone.0221897. eCollection 2019.

51. Greeson J, Eisenlohr-Moul T. Chapter 12. Mindfulness-Based Stress Reduction for Chronic Pain. In: Baer RA, ed. Practical Resources for the Mental Health Professional, Mind-fulness-Based Treatment Approaches. 2nd ed. Academic Press; 2014. P. 269-92. doi: 10.1016/b978-0-12-416031-6.00012-8

52. Lauche R, Cramer H, Dobos G, et al. A systematic review and meta-analysis of mindfulness-based stress reduction for the fibromyalgia syndrome (Provisional abstract). J Psychosom Res. 2013 Dec;75(6):500-10. doi: 10.1016/j.jpsychores.2013.10.010. Epub 2013 Oct 26.

53. Perez-Aranda A, D'Amico F, Feliu-Soler A, et al. Cost-Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study). J Clin Med. 2019;8(7):1068. doi: 10.3390/jcm8071068

54. Sosa-Reina MD, Nunez-Nagy S, Gallego-Izquierdo T, et al. Effectiveness of Therapeutic Exercise in Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. BioMed Res Int. 2017;2017:1-14. doi: 10.1155/2017/2356346

55. Estevez-Lopez F, Maestre-Cascales C, Russell D, et al. Effectiveness of exercise on fatigue and sleep quality in fibromyalgia: a systematic review and meta-analysis of randomised trials. Arch Phys Med Rehabil. 2021 Apr;102(4):752-61. doi: 10.1016/j.apmr.2020.06.019. Epub 2020 Jul 25.

56. Glombiewski JA, Bernardy K, Häuser W. Efficacy of EMG- and EEG-Biofeedback in Fibromyalgia Syndrome: A Meta-Analysis and a Systematic Review of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2013;2013:962741. doi: 10.1155/2013/962741. Epub 2013 Sep 3.

57. Baumueller E, Winkelmann A, Irnich D, et al. Electromyogram biofeedback in patients with fibromyalgia: a randomized controlled trial. Complement Med Res. 2017;24(1):33-9. doi: 10.1159/000454692

58. Kim J, Kim SR, Lee H, Nam DH. Comparing Verum and Sham Acupuncture in Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2019 Aug 25;2019:8757685. doi: 10.1155/2019/8757685. eCollection 2019.

59. Galvez-Sanchez CM, Duschek S, Reyes Del Paso GA. Psychological impact of fibromyalgia: current perspectives. Psychol Res Behav Manag. 2019 Feb 13;12:117-127. doi: 10.2147/PRBM.S178240. eCollection 2019.

60. Shilov VV. Otkrytoye, randomizirovannoye, perekrestnoye issledovaniye sravnitel'noy farmakokinetiki i bioekvivalentnosti preparatov Duloksetin Kanon, kapsuly 60 mg (ZAO «Kanonfarma prodakshn», Rossiya) i Simbalta® , kapsuly 60 mg («Lilli S.A.», Ispaniya»). 2012 [An open, randomized, cross-sectional study of the comparative pharmacokinetics and bioequivalence of the drugs Duloxetine Canon, 60 mg capsules (Kanonfarma Production CJSC, Russia) and Simbalta® , 60 mg capsules (Lilly S. A., Spain). 2012]. Available from: https://clinline.ru/reestr-klinicheskih-issledovanij/897-19.04.2012.html (In Russ.).

61. Sardaryan IS. Otkrytoye, randomizirovannoye, perekrestnoye issledovaniye sravnitel'noy farmakokinetiki i bioekvivalentnosti preparatov Pregabalin Kanon, kapsuly, 300 mg (ZAO Kanonfarma Prodakshn, Rossiya) i Lirika® , kapsuly 300 mg (Pfayzer GmbKH, Germaniya). 2013 [An open, randomized, cross-sectional study of the comparative pharmacokinetics and bioequivalence of the drugs Pregabalin Canon, capsules, 300 mg (Kanonpharma Production CJSC, Russia) and Lyrica® , capsules 300 mg (Pfizer GmbH, Germany). 2013]. Available from: https://clinline.ru/reestr-klinicheskih-issledovanij/286-30.04.2013.html (In Russ.).


For citation:


Nasonova T.I., Mukhametzyanova A.K., Tabeyeva G.R., Chernousov P.A. Modern approaches to the treatment of fibromyalgia. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):83-89. (In Russ.) https://doi.org/10.14412/2074-2711-2021-5-83-89

Views: 84


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)